PANACEABIO

Panacea Biotec Share Price

₹414.00 +19.7 (5%)

21 Nov, 2024 14:13

SIP TrendupStart SIP in PANACEABIO

Start SIP

Performance

  • Low
  • ₹395
  • High
  • ₹414
  • 52 Week Low
  • ₹112
  • 52 Week High
  • ₹414
  • Open Price₹414
  • Previous Close₹394
  • Volume331,143

Investment Returns

  • Over 1 Month + 20.54%
  • Over 3 Month + 113.8%
  • Over 6 Month + 200.33%
  • Over 1 Year + 169.44%
SIP Lightning

Smart Investing Starts Here Start SIP with Panacea Biotec for Steady Growth!

Invest Now

Panacea Biotec Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -173.3
  • PEG Ratio
  • 0.7
  • Market Cap Cr
  • 2,536
  • P/B Ratio
  • 3.1
  • Average True Range
  • 20.96
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 15.45
  • RSI
  • 65.51
  • MFI
  • 68.48

Panacea Biotec Financials

Panacea Biotec Technicals

EMA & SMA

Current Price
₹414.00
+ 19.7 (5%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹347.86
  • 50 Day
  • ₹313.10
  • 100 Day
  • ₹267.27
  • 200 Day
  • ₹221.62

Resistance and Support

394.3 Pivot Speed
  • R3 394.30
  • R2 394.30
  • R1 394.30
  • S1 394.30
  • S2 394.30
  • S3 394.30

What's your outlook on Panacea Biotec?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Panacea Biotec is a biotechnology company specializing in research, development, and manufacturing of vaccines, pharmaceuticals, and biosimilars. It operates state-of-the-art facilities in India, serving global markets across North America, Europe, and emerging economies.

Panacea Biotec (Nse) has an operating revenue of Rs. 550.03 Cr. on a trailing 12-month basis. An annual revenue growth of 14% is good, Pre-tax margin of 0% needs improvement, ROE of -0% is poor and needs improvement. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 22% and 104% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 9% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 30 which is a POOR score indicating inconsistency in earnings, a RS Rating of 96 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 36 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Panacea Biotec Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-13 Quarterly Results
2024-08-14 Quarterly Results
2024-05-30 Audited Results
2024-02-13 Quarterly Results
2023-11-10 Quarterly Results

Panacea Biotec F&O

Panacea Biotec Shareholding Pattern

72.87%
0%
0.37%
18.11%
8.65%

About Panacea Biotec

  • NSE Symbol
  • PANACEABIO
  • BSE Symbol
  • 531349
  • Chairman & Managing Director
  • Dr. Rajesh Jain
  • ISIN
  • INE922B01023

Similar Stocks to Panacea Biotec

Panacea Biotec FAQs

Panacea Biotec share price is ₹414 As on 21 November, 2024 | 13:59

The Market Cap of Panacea Biotec is ₹2535.8 Cr As on 21 November, 2024 | 13:59

The P/E ratio of Panacea Biotec is -173.3 As on 21 November, 2024 | 13:59

The PB ratio of Panacea Biotec is 3.1 As on 21 November, 2024 | 13:59

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23